Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s11096-024-01721-1
Published Online: 2024-04-20
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Huang, Zijia
Zhou, Lingyan
Zheng, Hanrui
Zhan, Mei http://orcid.org/0000-0003-0226-3480
Text and Data Mining valid from 2024-04-20
Version of Record valid from 2024-04-20
Article History
Received: 7 November 2023
Accepted: 3 March 2024
First Online: 20 April 2024
Conflicts of interest
: The authors have no conflicts of interest to declare.